Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Shiina, Takayuki*; Tsuchiya, Kunihiko; Nagai, Yasuki; Morikawa, Yasumasa*; Takeuchi, Nobuhiro*
no journal, ,
According to statistical data reported by the Japan Radioisotope Association (JRIA) in 2014, the Mo/
Tc generator and
Tc injections (
Tc labeled pharmaceuticals) continues to account for approximately 80% of the entire in-vivo supply in Japan. Furthermore, the number of
Tc injection supplies is approximately four times larger than that of the
Mo/
Tc generator. Therefore, Chiyoda Technol Co. have performed a research and development (R&D) for the domestic production of
Tc in cooperation with the Japan Atomic Energy Agency (JAEA) and FUJIFILM RI pharma Co., Ltd. to ensure a constant and reliable supply of
Tc. CTC therefore has a plan to stably produce
Tc from
Mo, which can be produced by the
Mo(n,
) reaction using the Japan Materials Testing Reactor (JMTR) and by the
Mo(n,2n) reaction using some new cyclotrons, and thereby to meet the Japanese demand for
Tc together with pharmaceutical companies in Japan. These production methods of
Mo were selected from viewpoints of safety, nuclear proliferation resistance and waste management. The specific activity of
Mo produced by these methods, however, is very low compared with that of (n,f)
Mo. Therefore, it is essential to develop some techniques for separation, concentration and recovery of
Tc, and it will be necessary to choose the best methods such as a wet method by solvent extraction and a dry method by sublimation, finally. In future, we aim to provide to about 20% of the domestic demand for
Mo using the JMTR and cyclotrons, 100-200 6-day Ci per week at the end of irradiation, and will carry out empirical studies for the commercial production of
Tc.